San Francisco, CA (PRWEB) May 04, 2014
TeselaGen Biotechnology (http://www.teselagen.com) has added veteran investor Tom Baruch to the Board of Directors as it begins commercialization of its software platform for accelerating synthetic biology. TeselaGen’s computer aided design and manufacturing platform is used around the world to develop biopharmaceuticals as well as novel bio-based approaches to sustainable chemicals and fuels.
Tom Baruch (http://en.wikipedia.org/wiki/Tom_Baruch) is a partner at Formation 8, a San Francisco venture capital firm and is the founder Baruch Future Ventures. Tom also serves on the board of the Sierra Club Climate Recovery Partnership, as a member of the "Brain Trust" of the ARPA-E program within the U.S. Department of Energy. Tom recently served as part of the IPO Task Force advising the U.S. Department of the Treasury in connection programs stimulating start-up activity in the US. In 1988, Tom founded CMEA Capital, an early-stage venture capital fund that managed $1.2 billion of capital and oversaw numerous IPOs and liquidity events. Prior to founding CMEA, Tom founded Microwave Technology, Inc., where he served as CEO for six years.
“Tom’s experience and depth of knowledge are a critical asset to us at our stage of growth”, said Mike Fero, CEO of TeselaGen. “We need bold advisors who are ready to take on the challenge of a business that spans the gap between information technology and biotechnology. This is a rarefied space that is very exciting, but you need experience in both sectors to understand and exploit the big opportunities that are presenting themselves right now.”
“I was very happy to get introduced to Mike and his co-founders”, said Baruch. “This is an all-star team that has solutions for difficult real world problems. They have a responsible vision for how synthetic biology can change lives by getting us to valuable therapeutics and sustainable chemicals faster and more cheaply.”
TeselaGen (http://www.teselagen.com) is a synthetic biology platform that enables the development of viral constructs, biologic medicines, and sustainably sourced chemicals. TeselaGen is privately held and is based in San Francisco, CA. Recently founded by three former Stanford fellows and a graduate of the QB3@953 incubator at UCSF (http://qb3.org/startups/incubators/953), the company has received early recognition in the form of two US National Science Foundation grants, a US Department of Energy grant and a Bio-IT World Best Practices Award. TeselaGen uses its proprietary Synthetic Evolution® technology for efficient rapid prototyping of recombinant molecules. The company's customers that are helping validate its approach include Amgen (USA), Genomatica (USA), and Redbiotec (Switzerland).